Pear Therapeutics Expands Platform with Digital Biomarkers, Machine Learning Algorithms and Sensor-Based Technologies

"BOSTON & SAN FRANCISCO--(BUSINESS WIRE)--Pear Therapeutics, Inc. announced today that it has entered into agreements with multiple technology companies, including Empatica Inc., etectRx, Inc., and KeyWise, Inc. The new technologies complement the voice-based biomarkers previously licensed from Winterlight Labs. These new agreements bolster Pear’s Prescription Digital Therapeutics (PDT) platform, by adding to its library of digital biomarkers, machine learning algorithms, sensor-based technologies, and digital therapeutics.

Pear has built the first scalable platform infrastructure to discover, develop, and deliver PDTs to patients. Pear’s continued investment in cutting-edge technologies supports its strategy to create a potent toolkit for the development of PDTs.

The newly licensed technologies enable the building of a comprehensive product offering for remote sensing of patient physiology. Pear’s physiologic sensing portfolio could allow for real-time personalization of digital therapeutic content and pharmaceutical dosing, creating the opportunity for enhanced patient outcomes across a wide range of disease states.

Pear is collaborating with Empatica, a pioneer in developing medical wearables and digital biomarkers, to explore using wearable sensors to evaluate withdrawal symptoms in patients with substance use disorder (SUD), opioid use disorder (OUD) and alcohol use disorder (AUD). Empatica’s smartwatches are FDA cleared and CE-marked, and are designed to track heart rate, fine locomotor behaviors, skin temperature, and skin conductance to quantify autonomic nervous system response.
Pear is collaborating with etectRx, Inc., an innovator in medication adherence technology, to explore the development of digital therapeutics combined with digital pills. etectRx’s ID-Cap™ System, a digital pill system that is FDA cleared as an ingestible event marker, is designed to guide digital, patient-centric, and value-based therapeutic interventions to enhance medication adherence and improve patient outcomes..." Lire la suite